Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13222947 | 1.00 | VDR (0.70) | VDRCYP24A1 | |
| SCHEMBL9009924 | 1.00 | VDR (0.70) | VDRCYP24A1 | |
| SCHEMBL12371673 | 1.00 | VDR (0.70) | VDRCYP24A1 | |
| SCHEMBL13666149 | 0.90 | VDR (0.61) | VDR | |
| Becocalcidiol SCHEMBL23752369 | 0.89 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL9009928 | 0.89 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL13666147 | 0.89 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL10820222 | 0.89 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL9010345 | 0.89 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL23752370 | 0.89 | VDR (0.76) | VDRCYP24A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143238-B2 | Methods of increasing epidermal skin thickness by topical administration of a 19-nor containing vitamin D compound | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-03-27 | — | — | US | disclosed |
| WO-2009111695-A8 | METHODS OF INCREASING EPIDERMAL SKIN THICKNESS BY TOPICAL ADMINISTRATION OF A 19-NOR CONTAINING VITAMIN D COMPOUND | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009111695-A1 | METHODS OF INCREASING EPIDERMAL SKIN THICKNESS BY TOPICAL ADMINISTRATION OF A 19-NOR CONTAINING VITAMIN D COMPOUND | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227545-A1 | METHODS OF INCREASING EPIDERMAL SKIN THICKNESS BY TOPICAL ADMINISTRATION OF A 19-NOR CONTAINING VITAMIN D COMPOUND | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2009-09-10 | — | — | US | disclosed |
| US-20080261925-A1 | COMPOUNDS, COMPOSITIONS, KITS AND METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2008-10-23 | — | — | US | disclosed |
| US-7208484-B2 | Method of synthesizing 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208484-B2 | Method of synthesizing 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261925-A1 | COMPOUNDS, COMPOSITIONS, KITS AND METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID | CYP2R1, CYP24A1, VDR | VDR 3/4885CYP24A1 2/4885 |
| US-20090227545-A1 | METHODS OF INCREASING EPIDERMAL SKIN THICKNESS BY TOPICAL ADMINISTRATION OF A 19-NOR CONTAINING VITAMIN D COMPOUND | CYP24A1, CYP2R1, VDR | VDR 3/4885CYP24A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.